Opiant Pharmaceuticals Inc (NASDAQ:OPNT) has been given an average broker rating score of 0.00 () from the zero analysts that provide coverage for the company, Zacks Investment Research reports.

Brokerages have set a 1-year consensus target price of $20.00 for the company and are anticipating that the company will post ($0.87) EPS for the current quarter, according to Zacks. Zacks has also given Opiant Pharmaceuticals an industry rank of 114 out of 265 based on the ratings given to related companies.

Shares of Opiant Pharmaceuticals (OPNT) traded down 24.90% during mid-day trading on Thursday, hitting $17.70. 152,599 shares of the stock were exchanged. Opiant Pharmaceuticals has a 12 month low of $5.00 and a 12 month high of $25.38. The firm has a market cap of $35.86 million and a P/E ratio of 6.66. The stock’s 50 day moving average is $9.38 and its 200 day moving average is $7.80.

Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings data on Wednesday, June 14th. The technology company reported ($1.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.73. Opiant Pharmaceuticals had a negative net margin of 17,271.58% and a negative return on equity of 245.18%. The company had revenue of $0.02 million for the quarter. Analysts expect that Opiant Pharmaceuticals will post $0.50 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.watchlistnews.com/opiant-pharmaceuticals-inc-opnt-receives-consensus-recommendation-of-from-brokerages/1469930.html.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Get a free copy of the Zacks research report on Opiant Pharmaceuticals (OPNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opiant Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.